In the last San Antonio Breast Cancer Symposium (SABCS), an analysis of patients in the SOFT trial showed that the Breast Cancer Index (BCI), a gene expression-based signature able to predict the risk of distant recurrence and the benefit of extended ET in early-stage HR+/HER2- BC, was able to identify women who would benefit from the addition of OFS and exemestane. Here, ERBB2 is linked to breast cancer.